Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 2 study of ACT001 alone or with temozolomide versus temozolomide or lomustine in first recurrent glioblastoma
CTR20202393Phase 2Completed
- Sponsor
- Accendatech
- Start
- Mar 2021
- Modality
- Metabolically Activated Prodrugs → Prodrugs/Conditional Activator Small Molecules → Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of dimethylaminomicheliolide in glioblastoma (GBM), sponsored by Accendatech. Started Mar 2021; status: completed.
02
Drugs
dimethylaminomicheliolide
03
Conditions
glioblastoma (GBM)
Beyond the preview
Go deeper on CTR20202393.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20202393.